PFE241011C33000
- 0.01
- 0.000.00%
Pfizer Newsroom
Express News | Obesity Drug Coverage Could Boost Spending By $35B Through 2034
Sector Update: Health Care
Pfizer's Bondholders Cheer News of Activist Investor Starboard's $1 Billion Investment
RSV vaccine sales plummet in the United States, as the 'most imaginative product' faces a heavy blow from the CDC.
①Independent pharmacists have reported that the demand for RSV vaccines in autumn has decreased by two-thirds compared to a year ago; ②In September last year, an average of about 0.44 million people per week received the glaxosmithkline or pfizer RSV vaccine; whereas this September, the average weekly number is around 0.157 million people.
Pfizer CEO's Job Is at Risk. A Shot of Discipline Could Help. -- WSJ
Daily short sale tracking: NVIDIA's short volume increased by 7 million, with a short sale ratio of 8%
GSK Arexvy Protects From RSV Over Three Full Seasons
glaxosmithkline (GSK.US) claimed that the protection of the RSV vaccine can last for three quarters.
glaxosmithkline (GSK.US) stated on Tuesday that its respiratory syncytial virus (RSV) vaccine has protective effects in the three quarters after vaccination.
UK Court Sides With Pfizer, BioNTech in MRNA Patent Case Against CureVac
Guggenheim Adjusts Pfizer Price Target to $36 From $35, Maintains Buy Rating
Watch These Pfizer Price Levels as Stock Gains After Report of Starboard Taking Stake
2 Covered Call Ideas on Pfizer Stock
CFRA Initiates Pfizer(PFE.US) With Hold Rating, Announces Target Price $31
Pfizer's Former CEO Pitches Board on Starboard's Shake up Plan, FT Reports
Express News | Pfizer, BioNTech Win Bid in UK Court to Invalidate CureVac's Patents Over Mrna Technology in Covid-19 Vaccines
Why Pfizer Will Find It Hard to Appease Its Activist Investor -- WSJ
TD Cowen Maintains Pfizer(PFE.US) With Hold Rating, Maintains Target Price $32
Wells Fargo Maintains Pfizer(PFE.US) With Hold Rating, Maintains Target Price $30
Pfizer Hold Rating: Balancing Valuation Concerns and Growth Challenges
Top Gap Ups and Downs on Monday: NVO, PFE, EQNR and More